


Psychopharmacology

Drugs, the Brain, and Behavior

SECOND EDITION

Jerrold S. Meyer
University of Massachusetts



Linda F. Quenzer
University of Hartford

Chapter 17, *Environmental Neurotoxicants
and Endocrine Disruptors*

by Susan A. Rice, Susan A. Rice and Associates, Inc.

Chapter 21, *Neurodegenerative Diseases*

by Jennifer R. Yates, Ohio Wesleyan University



Sinauer Associates, Inc. • Publishers
Sunderland, Massachusetts U.S.A.

Brief Contents

CHAPTER 1	Principles of Pharmacology	3
CHAPTER 2	Structure and Function of the Nervous System	41
CHAPTER 3	Chemical Signaling by Neurotransmitters and Hormones	77
CHAPTER 4	Methods of Research in Psychopharmacology	107
CHAPTER 5	Catecholamines	143
CHAPTER 6	Serotonin	167
CHAPTER 7	Acetylcholine	185
CHAPTER 8	Glutamate and GABA	201
CHAPTER 9	Drug Abuse and Addiction	227
CHAPTER 10	Alcohol	265
CHAPTER 11	The Opioids	305
CHAPTER 12	Psychomotor Stimulants: Cocaine and the Amphetamines	339
CHAPTER 13	Nicotine and Caffeine	373
CHAPTER 14	Marijuana and the Cannabinoids	401
CHAPTER 15	Hallucinogens, PCP, and Ketamine	429
CHAPTER 16	Inhalants, GHB, and Anabolic–Androgenic Steroids	451
CHAPTER 17	Environmental Neurotoxicants and Endocrine Disruptors	477
CHAPTER 18	Anxiety Disorders: Sedative–Hypnotic and Anxiolytic Drugs	509
CHAPTER 19	Affective Disorders: Antidepressants and Mood Stabilizers	543
CHAPTER 20	Schizophrenia: Antipsychotic Drugs	575
CHAPTER 21	Neurodegenerative Diseases	611

Contents

Preface xviii

1

Principles of Pharmacology 3

Pharmacology: The Science of Drug Action 3

BOX 1.1 *Naming Drugs* 5

Pharmacokinetic Factors Determining Drug Action 6

Methods of drug administration influence the onset of drug action 7

BOX 1.2 *Treating Autism with Intranasal Oxytocin* 10

Multiple factors modify drug absorption 12

Drug distribution is limited by selective barriers 15

Depot binding alters the magnitude and duration of drug action 18

Biotransformation and elimination of drugs contribute to bioavailability 19

Therapeutic Drug Monitoring 24

Pharmacodynamics:

Drug–Receptor Interactions 25

BOX 1.3 *Drug Categories* 26

Extracellular and intracellular receptors have several common features 27

Dose–response curves describe receptor activity 29

The therapeutic index calculates drug safety 30

Receptor antagonists compete with agonists for binding sites 31

Biobehavioral Effects of Chronic Drug Use 32

Repeated drug exposure can cause tolerance 32

Chronic drug use can cause sensitization 36

Pharmacogenetics and Personalized Medicine in Psychiatry 36

2

Structure and Function of the Nervous System 41

Cells of the Nervous System 42

BOX 2.1 *Embryonic Stem Cells* 43

Neurons have three major external features 44

Characteristics of the cell membrane are critical for neuron function 49

Glial cells provide vital support for neurons 50

Electrical Transmission within a Neuron 52

Ion distribution is responsible for the cell's resting potential 52

Local potentials are small, transient changes in membrane potential 53

Sufficient depolarization at the axon hillock opens voltage-gated Na^+ channels, producing an action potential 55

Drugs and poisons alter axon conduction 56

Organization of the Nervous System 58

The nervous system comprises the central and peripheral divisions 58

BOX 2.2 *Finding Your Way in the Nervous System* 60

CNS functioning is dependent on structural features 63
 The CNS has six distinct regions reflecting embryological development 63

BOX 2.3 *Neuroendocrine Response to Stress* 69

The cerebral cortex is divided into four lobes, each having primary, secondary, and tertiary areas 70

Rat and human brains have many similarities and some differences 72

3

Chemical Signaling by Neurotransmitters and Hormones 77

Chemical Signaling between Nerve Cells 78

Neurotransmitter Synthesis, Release, and Inactivation 79

Neurotransmitters encompass several different kinds of chemical substances 80

Classical transmitters and neuropeptides are synthesized by different mechanisms 81

Neuromodulators are chemicals that don't act like typical neurotransmitters 82

Neurotransmitter release involves the exocytosis and recycling of synaptic vesicles 82

Several mechanisms control the rate of neurotransmitter release by nerve cells 84

Neurotransmitters are inactivated by reuptake and by enzymatic breakdown 85

Neurotransmitter Receptors and Second-Messenger Systems 87

There are two major families of neurotransmitter receptors 87

Second messengers work by activating specific protein kinases within a cell 90

BOX 3.1 *Just Say No* 91

Tyrosine kinase receptors mediate the effects of neurotrophic factors 92

Pharmacology of Synaptic Transmission 93

Synaptic Plasticity 94

The Endocrine System 96

Endocrine glands can secrete multiple hormones 96

Mechanisms of hormone action vary 99

Why is the endocrine system important to pharmacologists? 100

BOX 3.2 *Sex Hormones and Drug Abuse* 101

4

Methods of Research in Psychopharmacology 107

Research Methods for Evaluating the Brain and Behavior 108

Techniques in Behavioral Pharmacology 108

Evaluating Animal Behavior 108

Animal testing needs to be valid and reliable to produce useful information 108

A wide variety of behaviors are evaluated by psychopharmacologists 110

BOX 4.1 *Using Drug Discrimination Testing* 117

BOX 4.2 *Drug Testing for FDA Approval* 118

Techniques in Neuropharmacology 121

Multiple Neurobiological Techniques for Assessing the CNS 121

Stereotaxic surgery is needed for accurate in vivo measures of brain function 121

Neurotransmitters, receptors, and other proteins can be quantified and visually located in the CNS 126

New tools are used for imaging the structure and function of the brain 132

Genetic engineering helps neuroscientists to ask and answer new questions 135

BOX 4.3 *Transgenic Model of Huntington's Disease* 137

Behavioral and neuropharmacological methods complement one another 139

5 Catecholamines 143

Catecholamine Synthesis, Release, and Inactivation 144

Tyrosine hydroxylase catalyzes the rate-limiting step in catecholamine synthesis 144

Catecholamines are stored in and released from synaptic vesicles 145

Catecholamine inactivation occurs through the combination of reuptake and metabolism 148

Organization and Function of the Dopaminergic System 149

Two important dopaminergic cell groups are found in the midbrain 149

Ascending dopamine pathways have been implicated in several important behavioral functions 150

There are five main subtypes of dopamine receptors organized into D₁- and D₂-like families 151

BOX 5.1 Mutations that Affect Dopamine Synthesis 152

Dopamine receptor agonists and antagonists affect locomotor activity and other behavioral functions 153

BOX 5.2 Using “Gene Knockout” Animals to Study the Dopaminergic System 155

Organization and Function of the Noradrenergic System 158

Norepinephrine is an important transmitter in both the central and peripheral nervous systems 158

Norepinephrine and epinephrine act through α - and β -adrenergic receptors 159

The central noradrenergic system plays a significant role in arousal, cognition, and the consolidation of emotional memories 159

Several medications work by stimulating or inhibiting peripheral adrenergic receptors 161

6 Serotonin 167

Serotonin Synthesis, Release, and Inactivation 168

Serotonin synthesis is regulated by enzymatic activity and precursor availability 168

Similar processes regulate storage, release, and inactivation of serotonin and the catecholamines 170

BOX 6.1 “Ecstasy”—Harmless Feel-Good Drug, Dangerous Neurotoxin, or Miracle Medication? 171

Organization and Function of the Serotonergic System 174

The serotonergic system originates in the brainstem and projects to all forebrain areas 174

There is a large family of serotonin receptors, most of which are metabotropic 174

Multiple approaches have identified several behavioral and physiological functions of serotonin 176

BOX 6.2 Serotonin and Aggression 177

7 Acetylcholine 185

Acetylcholine Synthesis, Release, and Inactivation 186

Acetylcholine synthesis is catalyzed by the enzyme choline acetyltransferase 186

Many different drugs and toxins can alter acetylcholine storage and release 186

Acetylcholinesterase is responsible for acetylcholine breakdown 187

BOX 7.1 Botulinum Toxin—Deadly Poison, Therapeutic Remedy, and Cosmetic Aid 188

Organization and Function of the Cholinergic System 190

Cholinergic neurons play a key role in the functioning of both the peripheral and central nervous systems 190

There are two acetylcholine receptor subtypes, nicotinic and muscarinic 191

BOX 7.2 Acetylcholine and Cognitive Function 192

8

Glutamate and GABA 201

Glutamate 202**Glutamate Synthesis, Release, and Inactivation 202**

Neurons generate glutamate from the precursor glutamine 202

Glutamate packaging into vesicles and uptake after release are mediated by multiple transport systems 202

Organization and Function of the Glutamatergic System 205

Glutamate is the neurotransmitter used in many excitatory pathways in the brain 206

Both ionotropic and metabotropic receptors mediate the synaptic effects of glutamate 206

AMPA and NMDA receptors play a key role in learning and memory 208

BOX 8.1 *Role of Glutamate Receptors in Long-Term Potentiation* 211

High levels of glutamate can be toxic to nerve cells 214

GABA 217**GABA Synthesis, Release, and Inactivation 217**

GABA is synthesized by the enzyme glutamic acid decarboxylase 217

GABA packaging into vesicles and uptake after release are mediated by specific transporter proteins 217

BOX 8.2 *GABA and Epilepsy* 218

Organization and Function of the GABAergic System 221

Some GABAergic neurons are interneurons, while others are projection neurons 221

The actions of GABA are mediated by ionotropic GABA_A receptors and metabotropic GABA_B receptors 221

9

Drug Abuse and Addiction 227

Introduction to Drug Abuse and Addiction 228

Drugs of abuse are widely consumed in our society 228

Drug use in our society has increased and has become more heavily regulated over time 229

Features of Drug Abuse and Addiction 232

Drug addiction is a chronic, relapsing behavioral disorder 232

BOX 9.1 *Should the Term "Addiction" Be Applied to Compulsive Behavioral Disorders That Don't Involve Substance Use?* 234

There are two types of progression in drug use 235

Which drugs are the most addictive? 237

Factors that Influence the Development and Maintenance of Drug Abuse and Addiction 238

The addiction potential of a substance is influenced by its route of administration 238

Most abused drugs exert rewarding and reinforcing effects 238

Drug dependence leads to withdrawal symptoms when abstinence is attempted 242

Discriminative stimulus effects contribute to drug-seeking behavior 243

Addiction is a heritable disorder 244

Psychosocial variables also contribute to addiction risk 245

The factors contributing to drug addiction can be combined into a biopsychosocial model 246

The Neurobiology of Addiction 248

Drug reward and reinforcement are mediated by a complex neuroanatomical and neurochemical circuit 248

BOX 9.2 *What Is the Role of Dopamine in Drug Reward?* 250

Neuroadaptive responses to repeated drug exposure are thought to underlie the development of addiction 252

Structural and functional abnormalities in the prefrontal cortex contribute to the symptoms of addiction 258

Is addiction a disease? 260

10 Alcohol 265

Psychopharmacology of Alcohol 266

- Alcohol has a long history of use 266
- What is an alcohol and where does it come from? 267
- The pharmacokinetics of alcohol determines its bioavailability 268
- Chronic alcohol use leads to both tolerance and physical dependence 270
- Alcohol affects many organ systems 273
- BOX 10.1** *The Role of Expectation in Alcohol-Enhanced Human Sexual Response* 274
- BOX 10.2** *Gender Differences in Alcohol Effects* 280

Neurochemical Effects of Alcohol 283

- Animal models are vital for alcohol research 283
- Alcohol acts on multiple neurotransmitters 284

Alcoholism 291

- Defining alcoholism and estimating its incidence have proved difficult 291
- The causes of alcoholism are multimodal 293
- Multiple treatment options provide hope for rehabilitation 297

11 The Opioids 305

Narcotic Analgesics 305

- The opium poppy has a long history of use 306
- Minor differences in molecular structure determine behavioral effects 307
- Bioavailability predicts both physiological and behavioral effects 308
- Opioids have their most important effects on the CNS and on the gastrointestinal tract 308

Opioid Receptors and Endogenous Neuropeptides 309

- Receptor binding studies identified and localized opioid receptors 309
- Four opioid receptor subtypes exist 310
- Several families of naturally occurring opioid peptides bind to these receptors 312
- BOX 11.1** *Opioid Modulation of Feeding* 314
- Opioid receptor-mediated cellular changes are inhibitory 315

Opioids and Pain 317

- The two components of pain have distinct features 318
- Opioids inhibit pain transmission at spinal and supra-spinal levels 320
- Other forms of pain control depend on opioids 321

Opioid Reinforcement, Tolerance, and Dependence 324

- Animal testing shows significant reinforcing properties 324
- Dopaminergic and nondopaminergic components contribute to opioid reinforcement 324
- Long-term opioid use produces tolerance, sensitization, and dependence 325
- Several brain areas contribute to the opioid abstinence syndrome 327
- BOX 11.2** *What is OxyContin?* 328
- Neurobiological adaptation and rebound constitute tolerance and withdrawal 329
- Environmental cues have a role in tolerance, drug abuse, and relapse 330

Treatment Programs for Opioid Addiction 331

- Detoxification is the first step in the therapeutic process 331
- BOX 11.3** *Role of NMDA Receptors in Tolerance and Dependence* 332
- Treatment goals and programs rely on pharmacological support and counseling 334

12 Psychomotor Stimulants: Cocaine and the Amphetamines 339

Cocaine 340

Background and History 340

Basic Pharmacology of Cocaine 342

Mechanisms of Cocaine Action 343

Acute Behavioral and Physiological Effects of Cocaine 345

Cocaine stimulates mood and behavior 345

Cocaine's physiological effects are mediated by the sympathetic nervous system 346

Dopamine is important for many effects of cocaine and other psychostimulants 346

BOX 12.1 *Is a Sweetened Water Solution More Reinforcing than Cocaine?* 347

Brain imaging has revealed the neural mechanisms of psychostimulant action in human subjects 350

Several DA receptor subtypes mediate the functional effects of psychostimulants 351

Cocaine Abuse and the Effects of Chronic Cocaine Exposure 352

Experimental cocaine use may escalate over time to a pattern of cocaine abuse and dependence 353

Animal models can stimulate the transition from recreational to compulsive cocaine use 354

Chronic psychostimulant exposure can give rise to tolerance or sensitization 356

Repeated or high-dose cocaine use can produce serious health consequences 358

Pharmacological, behavioral, and psychosocial methods are used to treat cocaine abuse and dependence 359

The Amphetamines 362

Background and History 362

Basic Pharmacology of the Amphetamines 364

Mechanisms of Amphetamine and Methamphetamine Action 364

Behavioral and Neural Effects of Amphetamines 365

Amphetamine and methamphetamine have therapeutic uses 365

High doses or chronic use of amphetamines can cause a variety of adverse effects 365

BOX 12.2 *Psychostimulants and ADHD* 366

Mephedrone and related drugs are gaining popularity as substitutes for other amphetamine-like compounds 370

13 Nicotine and Caffeine 373

Nicotine 374

Background and History 374

Basic Pharmacology of Nicotine and Its Relationship to Smoking 375

Mechanisms of Action 376

Behavioral and Physiological Effects 377

Nicotine elicits different mood changes in smokers compared with nonsmokers 377

Nicotine enhances cognitive function 377

Nicotine's reinforcing effects are mediated by activation of the mesolimbic dopamine system 379

Nicotine produces a wide range of physiological effects 381

Nicotine is a toxic substance that can be fatal at high doses 381

Chronic exposure to nicotine induces tolerance and dependence 381

Cigarette Smoking 384

How many people smoke, and who are they? 384

Cigarette smokers progress through a series of stages in their smoking behavior 385

Why do smokers smoke? 385

BOX 13.1 *What Is the Progression from First Cigarette to an Established Pattern of Smoking?* 386

Smoking is a major cause of illness and premature death 390

Behavioral and pharmacological strategies are used to treat tobacco dependence 390

Caffeine 393

Background 393

Basic Pharmacology of Caffeine 394

Behavioral and Physiological Effects 394

- Acute subjective and behavioral effects of caffeine depend on dose and prior exposure 394
- Caffeine consumption can enhance sports performance 395
- Regular caffeine use leads to tolerance and dependence 395

Caffeine and caffeine-like drugs pose health risks but also exert therapeutic benefits 396

Mechanisms of Action 397

BOX 13.2 *Do Caffeine-Containing Energy Drinks Pose a Risk to Your Health?* 398

14 Marijuana and the Cannabinoids 401**Background and History of Marijuana 402****Basic Pharmacology of Marijuana 403****Mechanisms of Action 405**

- Cannabinoid effects are mediated by cannabinoid receptors 405
- Pharmacological studies reveal the functional roles of cannabinoid receptors 406
- Endocannabinoids are cannabinoid receptor agonists synthesized by the body 407

BOX 14.1 *Therapeutic Uses of Cannabinoids* 410

Acute Behavioral and Physiological Effects of Cannabinoids 413

Cannabis consumption produces a dose-dependent state of intoxication 413

Marijuana use can lead to deficits in cognition and psychomotor performance 415

Cannabinoids are reinforcing to both humans and animals 416

Cannabis Abuse and the Effects of Chronic Cannabis Exposure 418

Tolerance and dependence can develop from chronic cannabinoid exposure 419

Chronic cannabis use may lead to adverse behavioral and health effects 422

BOX 14.2 *Is There a Relationship between Early Heavy Marijuana Smoking and Later Risk for Developing Psychosis?* 424

15 Hallucinogens, PCP, and Ketamine 429**Hallucinogenic Drugs 430****Mescaline 430****Psilocybin 430****Dimethyltryptamine and 5-Methoxy-Dimethyltryptamine 432****LSD 432**

BOX 15.1 *The Discovery of LSD* 433

Salvinorin A 434**Pharmacology of Hallucinogenic Drugs 435**

- Different hallucinogenic drugs vary in potency and in their time course of action 435
- Hallucinogens produce a complex set of psychological and physiological responses 435
- Most hallucinogenic drugs share a common indoleamine or phenethylamine structure 437
- Indoleamine and phenethylamine hallucinogens are 5-HT_{2A} receptor agonists 438

Salvinorin A is a κ -opioid receptor agonist 439

The neural mechanisms underlying hallucinogenesis are not yet fully understood 439

Hallucinogenic drug use leads to adverse effects in some users 440

PCP and Ketamine 442**Background and History 442****Pharmacology of PCP and Ketamine 443**

PCP and ketamine produce a state of dissociation 443

PCP and ketamine are noncompetitive antagonists of NMDA receptors 444

PCP and ketamine have significant abuse potential 444

BOX 15.2 *Getting High on Cough Syrup* 446

PCP or ketamine exposure can cause a variety of adverse consequences 447

Novel therapeutic applications have been proposed for ketamine 448

16

Inhalants, GHB, and Anabolic–Androgenic Steroids 451

Inhalants 452**Background 452**

Inhalants comprise a range of substances including volatile solvents, aerosols, and gases 452

These substances are particularly favored by children and adolescents 452

Behavioral and Neural Effects 452

Many inhalant effects are similar to alcohol intoxication 452

Chronic inhalant use can lead to tolerance and dependence 453

Rewarding and reinforcing effects have been demonstrated in animals 454

Inhalants are central nervous system (CNS) depressants 454

Health risks associated with inhalant abuse 455

Gamma-Hydroxybutyrate 457**Background 457**

BOX 16.1 “Date Rape” Drugs 458

Behavioral and Neural Effects 459

GHB produces behavioral sedation, intoxication, and learning deficits 459

Evidence for GHB reinforcement in animal studies has been inconsistent 460

Effects of GHB are mediated by multiple mechanisms 460

Medical and Recreational Uses of GHB 461

GHB is used therapeutically for the treatment of narcolepsy and alcoholism 461

GHB has significant abuse potential when used recreationally 462

Anabolic–Androgenic Steroids 464**Background and History 464**

Anabolic steroids are structurally related to testosterone 464

Anabolic steroids were developed to help build muscle mass and enhance athletic performance 464

Anabolic steroids are currently taken by many adolescent and adult men 466

Anabolic steroids are taken in specific patterns and combinations 466

Pharmacology of Anabolic Steroids 468

Research is beginning to unravel the mechanism of action of anabolic steroids on muscle 468

Many adverse side effects are associated with anabolic steroid use 469

Regular anabolic steroid use causes dependence in some individuals 471

BOX 16.2 Anabolic Steroids and “Roid Rage” 472

17

Environmental Neurotoxicants and Endocrine Disruptors 477

Neurotoxicity 478**Endocrine Disruptors 480**

Hypothalamic–Pituitary–Gonadal (HPG) System 481

Hypothalamic–Pituitary–Thyroid (HPT) System 481

Persistent and Semi-Persistent Organic Pollutants 484**Polychlorinated Biphenyls (PCBs) 485**

Neurotoxicity in adults 485

Neurotoxicity in children and the developing nervous system 486

Mechanisms of action 486

Polybrominated Diphenyl Ethers (PBDEs) 487

Neurotoxicity in adults 487

Neurotoxicity in children and the developing nervous system 488

Mechanisms of action 488

Bisphenol A (BPA) 489

Neurotoxicity in children and the developing nervous system 489

Mechanisms of action 490

Insecticides 490**Organophosphate Insecticides 491**

Neurotoxicity in adults 492

Neurotoxicity in children and the developing nervous system 494

Mechanisms of action 494

Pyrethrin and Pyrethroid Insecticides 495

- Acute neurotoxicity 495
- Developmental neurotoxicity 496
- Mechanisms of action 496

Toxic Metals 498**Lead (Pb) 498**

- Neurotoxicity in adults 499
- Neurotoxicity in children and the developing nervous system 499
- Mechanisms of action 499

Mercury (Hg) 500

- Neurotoxicity in adults 501
- BOX 17.1** *Thimerosal in Vaccinations—Does It Cause Autism?* 502
- Developmental neurotoxicity 503
- Mechanisms of action 504

Arsenic (As) 504

- Neurotoxicity in adults 505
- Neurotoxicity in children and the developing nervous system 505
- Mechanisms of action 506

18 Anxiety Disorders: Sedative–Hypnotic and Anxiolytic Drugs 509**Neurobiology of Anxiety 510**

- What is anxiety? 510
- The amygdala is central to emotion processing circuits 511
- Multiple neurotransmitters mediate anxiety 513
- Genes and environment interact to determine the tendency to express anxiety 519
- The effects of early stress are dependent on timing and gender 521

Characteristics of Anxiety Disorders 524**BOX 18.1** *Neurobiological Model of OCD* 529**Drugs for Treating Anxiety 531**

- Barbiturates are the oldest sedative–hypnotics 533
- Benzodiazepines are highly effective for anxiety reduction 535
- Second-generation anxiolytics produce distinctive clinical effects 538
- Antidepressants relieve anxiety and depression 539
- Many novel approaches to treating anxiety are being developed 540

19 Affective Disorders: Antidepressants and Mood Stabilizers 543**Characteristics of Affective Disorders 544**

- Major depression damages the quality of life 544
- In bipolar disorder moods alternate from mania to depression 545
- Risk factors for mood disorders are biological and environmental 546

BOX 19.1 *Stress–Diathesis Model of Depression* 548**BOX 19.2** *Agomelatine* 550**Animal Models of Affective Disorders 550****Neurochemical Basis of Mood Disorders 553**

- Serotonin dysfunction contributes to mood disorders 554
- Norepinephrine activity is altered by antidepressants 557

Norepinephrine and serotonin modulate one another 557

Neurobiological Models of Depression 558**BOX 19.3** *Epigenetic Modifications in Psychopathology and Treatment* 560**Therapies for Affective Disorders 563**

- Monoamine oxidase inhibitors are the oldest antidepressant drugs 564
- Tricyclic antidepressants block the reuptake of norepinephrine and serotonin 564
- Second-generation antidepressants have different side effects 567
- Third-generation antidepressants have distinctive mechanisms of action 568
- Drugs for treating bipolar disorder stabilize the highs and the lows 569

20 Schizophrenia: Antipsychotic Drugs 575

Characteristics of Schizophrenia 576

- There is no defining cluster of schizophrenic symptoms 576
- Long-term outcome depends on pharmacological treatment 577

Etiology of Schizophrenia 578

- Abnormalities of brain structure and function occur in individuals with schizophrenia 579
- Genetic, environmental, and developmental factors interact 580

BOX 20.1 *Epigenetic Modifications and Risk for Schizophrenia* 584

Preclinical Models of Schizophrenia 586

Neurochemical Models of Schizophrenia 589

- Abnormal dopamine function contributes to schizophrenic symptoms 589

BOX 20.2 *The Neonatal Ventral Hippocampal Lesion Model of Schizophrenia* 590

The neurodevelopmental model integrates anatomical and neurochemical evidence 591

Glutamate and other neurotransmitters contribute to symptoms 592

Classic Neuroleptics and Atypical Antipsychotics 594

Phenothiazines and butyrophenones are traditional neuroleptics 594

Dopamine receptor antagonism is responsible for antipsychotic action 596

Side effects are directly related to neurochemical action 598

Atypical antipsychotics are distinctive in several ways 602

Practical clinical trials help clinicians make decisions about drugs 605

There are renewed efforts to treat the cognitive symptoms 606

21 Neurodegenerative Diseases 611

Parkinson's Disease and Alzheimer's Disease 612

Parkinson's Disease 612

- The clinical features of PD are primarily motor related 612
- Parkinson's patients may also develop dementia 613
- The primary pathology of PD is a loss of dopaminergic neurons in the substantia nigra 613
- Animal models of PD have strengths and limitations 616
- Pharmacological treatments for PD are primarily symptomatic, not disease-altering 616

BOX 21.1 *Betting with Parkinson's Disease* 618

There are several unmet needs in PD diagnosis and treatment 618

Alzheimer's Disease 619

AD is defined by several pathological cellular disturbances 620

There are several behavioral, health, and genetic risk factors for AD 622

Alzheimer's disease cannot be definitively diagnosed until postmortem analysis 623

Several different animal models contribute to our understanding of AD 624

Symptomatic treatments are available and several others are under study for slowing disease progression 624

BOX 21.2 *Measles, Mumps, and ... Alzheimer's Vaccines?* 626

Other Major Neurodegenerative Diseases 626

Huntington's Disease 626

Symptoms 627

Only symptomatic treatments are available for HD, none alter disease progression 628

Amyotrophic Lateral Sclerosis 628

- The symptoms and disease progression in ALS are devastating 628
- The loss of motor neurons in ALS is complicated and poorly understood 628
- Only one medication is FDA-approved for use in ALS 629

Multiple Sclerosis 629

- The symptoms of MS are variable and unpredictable 630
- Diagnosis 630
- Causes of MS 631
- Treatments fall into several categories for MS and can be very effective 632

Glossary 635

Illustration Credits 659

References 661

Author Index 693

Subject Index 699